Thesis TrackerFrazis Capital Partners
Companies discussed, last 12 months
0 companies, monthly, latest action on the rightNo commentary in the last 12 months.
Commentary
18 Jul 2025Frazis Capital PartnersCU6InitiatedThe fund initiated a position in Clarity Pharmaceuticals after the stock experienced a classic momentum unwind from its prior highs and the share price reached levels at which the manager believes the fundamental opportunity is priced in. The manager highlights approximately 600,000 US men with high PSA who test negative on current screens as a large addressable market for Clarity's diagnostic, and notes that as the company approaches its 2027 revenue milestones, the market's time horizon is extending. The manager bought steadily at an average of $1.69.
23 Apr 2025Frazis Capital PartnersCU6IncreasedThe fund manager continues to hold Clarity Pharmaceuticals (CU6), providing a detailed analysis of the company's situation following significant share price weakness driven by a broader biotech sell-off, short-selling, and momentum unwind rather than company-specific setbacks. The manager acknowledges a challenging market environment but highlights consistent positive clinical data across diagnostic and therapeutic programs. The manager recently bought back previously sold shares and describes Clarity as approximately 8% of the portfolio, noting the risk-reward is more attractive now than a year ago given more data with a substantially lower valuation.
About Frazis Capital Partners
Growth Focused, All-CapFrazis Capital Partners is a boutique fund manager founded by Michael Frazis, specializing in high-growth global equities with a strong emphasis on innovative technology, healthcare and disruptive businesses, including significant exposure to Chinese and US growth companies. The fund runs a concentrated, long-only portfolio built around long-duration structural growth themes such as electric vehicles, artificial intelligence, biotechnology and internet platforms. Frazis is known for detailed, publicly shared investment theses and a willingness to hold volatile, high-conviction positions for years to capture compounding growth. The strategy targets wholesale investors seeking exposure to global secular growth trends rather than traditional value or income-style investing.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.